Who Paid My Doc
Michael Bookman
Medical Oncology Tucson, AZ Medical Doctor
NPI 1972570836 CMS profile 271230
1515 N Campbell Ave, Room 1903, Tucson, AZ 85724
General payments
$46,090
Research payments
$2,701
Ownership & investment interest
$0
Research they led as principal investigator
$4,727,977
Through program year 2025, Michael Bookman of Tucson, AZ is reported in the CMS Open Payments database as having received $46,090 across 36 general payments and $2,701 in research payments paid to them. Separately, studies naming them as principal investigator received $4,727,977 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 82nd percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $17,909 | 7 | |
| 2024 | General | $73 | 1 | |
| 2023 | General | $1,726 | 4 | |
| 2022 | General | $121 | 1 | |
| 2021 | Research | $2,137 | 6 | |
| 2020 | General | $18,326 | 12 | |
| 2020 | Research | $542 | 2 | |
| 2019 | General | $7,936 | 11 | |
| 2019 | Research | $22 | 1 |
Beside peers
- Michael Bookman
- Medical Oncology median
- Middle half of Medical Oncology
- National median
In program year 2025, general payments to Michael Bookman were reported at $17,909. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.
Show as a table
| Year | Michael Bookman | Medical Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $7,936 | $968 | $140–$6,658 | $163 |
| 2020 | $18,326 | $747 | $102–$5,891 | $114 |
| 2021 | $0 | $430 | $50–$4,098 | $132 |
| 2022 | $121 | $812 | $127–$4,907 | $149 |
| 2023 | $1,726 | $957 | $144–$5,248 | $160 |
| 2024 | $73 | $1,042 | $149–$5,650 | $164 |
| 2025 | $17,909 | $1,128 | $147–$5,675 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 8 drugsPart D claims
170
Drug cost
$1,520,146
Branded share of claims
70%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Zejula Niraparib Tosylate | Brand | 45 | $837,714 | |
| Ibrance Palbociclib | Brand | 36 | $555,472 | |
| Lynparza Olaparib | Brand | 14 | $126,125 | |
| Lorazepam | Generic | 20 | $222 | |
| Ondansetron Hcl | Generic | 19 | $172 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 11 | $170 | |
| Dexamethasone | Generic | 12 | $136 | |
| Zolpidem Tartrate Er Zolpidem Tartrate | Brand | 13 | $134 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.
Records
45 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Medical Oncology in Arizona
Related records
Medical Oncology in Arizona
Practitioners in the same specialty and state, ranked by reported value.
All Medical Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Arizona
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.